Bictegravir 1611493-60-7
wehewehe
ʻO Bictegravir kahi puke moʻolelo, hoʻopaneʻe ikaika o HIV-1 integrase me kahi IC50 o 7.5 nM.
In Vitro
Kāohi ʻo Bictegravir (BIC) i ka hana hoʻoili strand me kahi IC50 o 7.5± 0.3 nM.E pili ana i kona kaohi ʻana i ka hana hoʻoili strand, ʻo Bictegravir kahi mea ʻoi aku ka nāwaliwali o 3.'- ka hana hoʻoponopono o HIV-1 IN, me kahi IC50 o 241±51 nM.Hoʻonui ʻo Bictegravir i ka hōʻiliʻili ʻana o nā pōʻai 2-LTR ~5-fold e pili ana i ka mana hoʻomāʻewaʻewa ʻia a hoʻemi i ka nui o nā huahana hoʻohui maoli i loko o nā cell i maʻi ʻia e 100-fold.Hoʻopaʻa ikaika ʻo Bictegravir i ka hoʻopiʻi hou ʻana o HIV-1 ma MT-2 a me MT-4 me nā EC50s o 1.5 a me 2.4 nM, kēlā me kēia.Hōʻike ʻo Bictegravir i nā hopena antiviral ikaika i nā lymphocytes CD4+ T mua a me nā macrophages i loaʻa i ka monocyte, me nā EC50 o 1.5±0.3 nM a me 6.6±4.1 nM, kēlā me kēia, i hoʻohālikelike ʻia me nā waiwai i loaʻa ma nā laina T-cell [1].
ʻAʻole ʻo MCE i hōʻoia kūʻokoʻa i ka pololei o kēia mau ʻano.No ka kuhikuhi wale no.
Helu NCT | Kākoʻo | Kūlana | Lā Hoʻomaka | Māhele |
NCT03998176 | Ke Kulanui o Nebraska|Gilead Science | HIV-1-ma'i | ʻOkakopa 9, 2019 | Māhele 4 |
NCT03789968 | Ke Kulanui ʻo Thomas Jefferson|Ke Kulanui o Maryland, College Park|Ke ola o ke Kulanui ʻo Indiana|Ka Halemai ʻo Brooklyn Halemai|Ke Kulanui o Illinois ma Chicago|Ke Kulanui o Nova Hikina Hema|Ke Kulanui o Kaleponi, Kapalakiko. | HIV+AIDS | Sepatemaba 1, 2019 | |
NCT04249037 | Ke Kulanui o Kololoka, Denver|ʻEpekema Gileada | HIV+AIDS | Malaki 1, 2020 | Pili 'ole |
NCT04132674 | Kikowaena ma'i Infectious o Wanekoua | Human Immunodeficiency Virus I Infection|Hoʻohana lāʻau | Nowemapa 26, 2018 | Māhele 4 |
NCT04054089 | Cristina Mussini|Ke Kulanui o Modena a me Reggio Emilia | Nā maʻi HIV | Kepakemapa 2019 | Māhele 4 |
NCT04155554 | Azienda Ospedaliera Universitaria Senese|Katolika University of the Sacred Heart|Ospedale Policlinico San Martino|Azienda Ospedaliera San Paolo|Ospedale Amedeo di Savoia | HIV-1-ma'i | Ianuali 29, 2020 | Māhele 3 |
NCT02275065 | ʻEpekema Gileada | Ma'i HIV-1 | ʻOkakopa 2014 | Māhele 1 |
NCT03711253 | Kulanui o Kaleponi Hema | ʻO ka maʻi HIV nui | ʻOkakopa 14, 2019 | Māhele 4 |
NCT02400307 | ʻEpekema Gileada | HIV | ʻApelila 17, 2015 | Māhele 1 |
NCT03499483 | Ola Kaiāulu ʻo Fenway | Kāohi HIV | Ianuali 24, 2019 | Māhele 4 |
NCT03502005 | Midland Research Group, Inc.|Gilead Sciences | ʻO ka maʻi hoʻomaʻemaʻe kino kanaka | Malaki 1, 2018 | Māhele 4 |
ʻO ke kinona
Manaʻo18Nā papahana Loiloi Kūlike Kūlike i ʻae ʻia4, a6nā papahana ma lalo o ka ʻae ʻia.
Ua hoʻokumu ka ʻōnaehana hoʻokele maikaʻi honua kiʻekiʻe i ke kumu kūʻai.
Holo ka nānā ʻana i ka maikaʻi ma ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic.
Kākoʻo ka hui ʻoihana Regulatory Affairs i nā koi maikaʻi i ka wā o ke noi a me ke kau inoa ʻana.